Drug Profile


Alternative Names: 18-MC

Latest Information Update: 25 Sep 2014

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Nonindustrial source
  • Class Alkaloids; Carboxylic acids; Drug withdrawal therapies; Esters
  • Mechanism of Action Alpha3beta4 nicotinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Drug abuse; Leishmaniasis

Most Recent Events

  • 23 Sep 2014 Phase-I clinical trials in Drug abuse (In volunteers) in Brazil (PO)
  • 23 Sep 2014 Phase-I clinical trials in Leishmaniasis (In volunteers) in Brazil (PO)
  • 03 Jan 2013 Savant HWP re-initiates development of 18-methylcoronaridine for the treatment of drug addiction, obesity and other forms of compulsive behaviour
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top